Therapy Directory

Palbociclib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention. Browse Palbociclib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

229

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Fulvestrant, Tamoxifen, Palbociclib; Drug
Lead sponsor: Shannon Puhalla; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer
Interventions: non-interventional; Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 301
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 224 more

Conditions: Advanced Breast Cancer, Treatment-Refractory Solid Tumors, Retinoblastoma Deficiency, SCLC, Soft Tissue Sarcoma, Endometrial Cancer, Bladder Cancer
Interventions: Palbociclib Oral Product, TAS-116; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Breast Neoplasms
Interventions: PF-06804103, PF-06804103 + Palbociclib +Letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 26
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 14 more

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib + an aromatase inhibitor, Palbociclib + Letrozole, Letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 813 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Carcinoma
Interventions: Binimetinib, Palbociclib, Trifluridine and Tipiracil Hydrochloride; Drug
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 7
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Wichita, Kansas + 4 more

Conditions: Breast Cancer, Solid Tumor, Adult
Interventions: APG-2575, Palbociclib; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Atlanta, Georgia • Austin, Texas • Houston, Texas + 1 more

Conditions: Breast Cancer, Metastatic Breast Cancer
Interventions: Prolonged Nightly Fasting, Exercise; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
Interventions: Palbociclib, T-DM1; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more

Conditions: Breast Cancer
Interventions: ZN-c5, Palbociclib; Drug
Lead sponsor: Zeno Alpha Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Tucson, Arizona • Los Angeles, California • Bethesda, Maryland + 6 more

Conditions: Breast Cancer
Interventions: Observation; Other
Lead sponsor: BioCorteX Inc; Industry
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Decatur, Illinois • Las Vegas, Nevada • Belleville, New Jersey + 3 more

About this Palbociclib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Palbociclib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Palbociclib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Palbociclib clinical trials

Filter and sort this therapy

Live official records

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.

Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib

Palbociclib in Real World Practice

TAS-116 Plus Palbociclib in Breast and Rb-null Cancer

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Feasibility of Fasting & Exercise in Pts With HR+ MBC

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

A Study of ZN-c5 in Subjects With Breast Cancer

Gut and Tumor Microbiome in Patients With Early Stage (II-III), Locally Advanced or Advanced ER-positive and HER2-negative Breast Cancer.

About this Palbociclib clinical trials directory page